Transmission of Tuberculosis Among Illicit Drug Use Linkages (TOTAL)

Tuberculosis (TB) is the leading infectious disease killer globally and leading cause of death in persons with HIV. The most effective way to reduce TB incidence and mortality is to interrupt transmission. This requires finding and treating individuals with TB disease early, including those with subclinical disease. Molecular epidemiologic studies and mathematical models have shown that the primary approach to case finding-household contact tracing-identifies only 8-19% of transmissions in high TB and TB/HIV burden settings. Thus there is a clear need to identify new groups and settings where TB transmission occurs. Spatial clustering of individuals with higher rates of progression from infection to disease, such as those with HIV and malnourishment, can also form transmission hotspots. Illicit drug (i.e., methamphetamines, crack/cocaine, opiates) users have higher TB infection prevalence and disease incidence compared to non-users, likely due to significant within-group transmission and/or clustered vulnerability. Increased transmission among people who use illicit drugs (PWUD) could result from creation of more efficient TB transmitters, increased close contact among transmitters, increased rates of primary progression from infection to disease among contacts, or a combination. Interrogation of illicit drug user networks for TB transmission, therefore, holds great potential as a target for early case identification and linkage to treatment, with potential benefit for halting transmission to the broader population.

Study Overview

• Status: Enrolling by invitation
• Conditions: Tuberculosis; Illicit Drug Use
• Intervention / Treatment: Behavioral: Smoked illicit drug use

Detailed Description

A cross-sectional, observational study design using respondent driven sampling (RDS) will be used for this research study.

In Aim 1, individuals will be recruited who currently use meth and/or Mandrax to assess TB exposure, incipient TB prevalence, and TB disease prevalence in the network. RDS will be used to seek out 750 meth/Mandrax users. Initial seeds (N=4) will be individuals from the investigator's current R01, the Tuberculosis treatment outcomes and alcohol use study (TRUST) cohort who have had active pulmonary TB disease in the prior 1-2 years and report current meth/Mandrax use.

For Aim 2, individuals from Aim 1 identified to have possible TB disease will be screened and enrolled to estimate the proportion that reflect recent transmission via genotyping and social epidemiologic links.

In Aim 3, the investigators will examine physiologic factors that may make PWUD more efficient TB transmitters. 50 PWUD participants from Aim 2 will be recruited who have active, untreated pulmonary TB and 50 individuals with active, untreated pulmonary TB who do not use meth/Mandrax, matched on age and gender will be recruited

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

Study Locations

• South Africa
  • Worcester, South Africa
    • Privately Rented Facility

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

750 PWUD in the Western Cape, South Africa will be enrolled into Aim 1. An anticipated 45-75 will have active TB disease and enrolled into Aim 2 and Aim 3 Arm 1 of the study.

50 people who do not smoke illicit drugs with active TB disease will be enrolled into Aim 3 Arm 2.

Description

Participants must be/have the following general inclusion criteria:

1. at least 15 years old
2. resident of the study community
3. intact mental status at enrollment (i.e., no acute intoxication)
4. provide written, informed consent to participate in the study if ≥18 years or written assent and parental consent if <18 years.
5. agree to comply with all study requirements, including provision of contact information and study appointments attendance

And for Aim 1:

1. self-reported meth or Mandrax use in the past month
2. urine drug screen positive for meth and/or Mandrax
3. all participants other than the seeds must also have evidence that they have been recruited by a peer (the coupon)

For Aim 2 participants must meet all general inclusion criteria and the inclusion criteria from Aim 1 (meth/Mandrax use) and:

(1) Have evidence of active TB disease on Xpert Ultra from their Aim 1 visit testing or report a recent TB diagnosis (within the past month)

For Aim 3 Arm 1 participants must meet all general inclusion criteria and the criteria under Aim 1 and Aim 2 (active illicit drug use and active TB)

And exclusion criteria:

1. No current pregnancy by urine pregnancy test
2. Not yet started on TB medication

For Aim 3 Arm 2 patients must meet all general inclusion criteria and the following inclusion criteria:

1. Attend the Worcester Community Day Clinic, the Empilisweni Clinic, or any other clinic and live in the general Worcester area
2. Have newly diagnosed TB

And exclusion criteria:

1. No self-reported drug use or evidence of drug use by urine test
2. No current pregnancy by urine pregnancy test
3. Not yet started TB medication

General exclusion criteria under all aims and arms of the study include:

1. Current drug or alcohol intoxication
2. Mental incapacitation to providing informed consent
3. Not currently or previously enrolled in any prophylactic TB therapy studies

Participants may also be excluded from the study under discretion of the Principal Investigator if the PI believes participation in the study may prove harmful to the participant or the research staff.

Participants will be enrolled from the main cohort (n=750) (Aim 1) into the additional cohorts under Aims 2 and Aim 3 Arm 1. Aim 3 Arm 2 will be recruited external to the main cohort (Aim 1)

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PWUD with active TB; People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease	Behavioral: Smoked illicit drug use; The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
PWUD with no active TB; People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease	Behavioral: Smoked illicit drug use; The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
non-PWUD with active TB; People who do not use meth/mandrax who have active TB disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
TB disease prevalence	Percentage of persons with TB disease based on results from Xpert Ultra and sputum culture	At baseline
Incipient TB prevalence	Percentage of persons with incipient TB based on host RNA signature	At baseline
Proportion of active TB cases resulting from recent transmission within this network of PWUD	Proportion of linked TB cases based on whole genome sequencing of the mycobacterium tuberculosis (Mtb) isolate and overlaying social epidemiological ties	Study duration - 3 years
Quantity of aerosolized Mtb in exhaled breath: amount of aerosolized Mtb exhaled in one hour	The amount of aerosolized Mtb exhaled in one hour in a specialized bio-aerosol capturing booth	One hour

Collaborators and Investigators

• Sponsor: Boston Medical Center
• Collaborators: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); University of Stellenbosch; Medical Research Council, South Africa; Desmond Tutu HIV Foundation/ University of Cape Town
• Investigators: Principal Investigator: Karen Jacobson, MD MPH, Boston Medical Center/ BUMC

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2021
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): April 1, 2024

Study Registration Dates

• First Submitted: November 1, 2019
• First Submitted That Met QC Criteria: November 4, 2019
• First Posted (Actual): November 5, 2019

Study Record Updates

• Last Update Posted (Actual): June 26, 2023
• Last Update Submitted That Met QC Criteria: June 23, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis
• Other Study ID Numbers: H-38910; 1R01AI147316-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No